Merck’s Board of Directors has approved a quarterly dividend of $0.85 per share for the second quarter of 2026, payable on April 7, 2026, to shareholders of record as of the close of business on March 16, 2026. This marks the company’s 14th consecutive annual increase in its dividend payout, reflecting Merck’s commitment to returning capital to investors through its robust free cash flow generation. The announcement follows the company’s reaffirmation of its full-year dividend policy during its recent earnings release, in which management highlighted strong balance sheet metrics and a target payout ratio in line with its investment-grade credit rating objectives.

Over the past six months, Merck’s share price has climbed approximately 41%, propelled by a 6% year-over-year increase in revenue and a 15% rise in adjusted net income during the latest quarter. Investor confidence has been bolstered by the solid performance of Merck’s flagship oncology portfolio, with double-digit growth in immuno-oncology treatments contributing significantly to top-line gains. Analysts have also pointed to the successful integration of recent product launches and pipeline progress as key drivers of the rally, citing upcoming clinical readouts in late-stage trials that could further support long-term earnings visibility.